← All trials
NCT04505787
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2020
- Primary completion
- Sep 9, 2020
- Completion date
- Sep 24, 2020
- First posted
- Aug 10, 2020
- Last posted
- Oct 22, 2020
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SocraTec R&D GmbHLead sponsor
- SocraMetrics GmbHCollaborator
- SocraTec R&D GmbHOverall official - principal investigator
- Teikoku Seiyaku Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.